Format

Send to

Choose Destination
Radiother Oncol. 2013 Jun;107(3):409-13. doi: 10.1016/j.radonc.2013.05.024. Epub 2013 Jun 14.

Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?

Author information

1
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. j.widder@umcg.nl

Abstract

BACKGROUND AND PURPOSE:

Stereotactic ablative radiotherapy (SABR; or stereotactic body radiotherapy, SBRT) emerges as treatment option for pulmonary oligometastatic disease (OMD), but there are no studies comparing SABR with pulmonary metastasectomy (PME). We analysed consecutive patients referred via a university-hospital based multidisciplinary team.

MATERIAL AND METHODS:

Patients were offered PME as first choice and SABR in case they were considered to be less suitable surgical candidates. Overall survival was the primary endpoint. Secondary endpoints were progression-free-survival, local control of treated metastases, and freedom-from-failure of a local-only treatment strategy without systemic therapy.

RESULTS:

From 2007 until 2010, 110 patients were treated and analysed (PME, n=68; SABR, n=42). Median follow-up time was 43 months (minimally, 25). Estimated overall survival rates at one, three, and five years were 87%, 62%, and 41% for PME, and 98%, 60%, and 49% for SABR, respectively (logrank-test, p=0.43). Local control at two years was 94% for SABR and 90% for PME. Progression-free survival was 17% at three years, but 43% of the patients still had not failed a local-only treatment strategy.

CONCLUSIONS:

Although SABR was second choice after PME, survival after PME was not better than after SABR. Prospective comparative studies are clearly required to define the role of both, SABR and PME in OMD.

KEYWORDS:

Oligometastatic disease; Pulmonary metastasectomy; Pulmonary oligometastases; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic oncology

PMID:
23773410
DOI:
10.1016/j.radonc.2013.05.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center